The Sub-Analysis of HFmrEF and HFrEF Group in CORE-HF Registry : When being Good is Not Enough
when being good is not enough
Abstract
Background : As the prevalence of heart failure (HF) kept rising each year, the burden caused by it also escalating, especially in terms of economic burden. This is urging the physician to quickly tackle the problem. Although HFrEF medications were developing vastly, the outcome of HF in real world still varies. This indicates another approach is still needed to manage HFrEF/HFmrEF comprehensively. This paper is aimed to give an overview of HFrEF and HFmrEF epidemiological data, based on CORE-HF real world data.
Methods : The CORE-HF is a single-center, prospective-cohort registry, which enrolls all patients with chronic HF, that were recruited consecutively from the outpatient Sebelas Maret HF Clinic. Both enrollment and follow-up have been performed since January 2018 until December 2022. Variables recorded consists of baseline characteristics, risk factors, subjective indicators, objective diagnostic assessments, therapies, and outcomes (readmission and mortality).
Results : The population of this registry was younger (58.7 ± 12.14) compared to other HF registries, with more multi comorbidities. The number of HFrEF patient was higher than HFmrEF (77.7% vs 22.3%), with clinically higher mortality rate (7.2% in the 1st year and 18.2% in the next year). Although triple therapy initiation and uptitration were excellent in number, the mortality rate during second year of follow-up was higher than other registries. We found non-compliant behavior to be responsible for those results.
Conclusion : Based on CORE-HF sub-analysis of the HFrEF and HFmrEF groups, adherence to HF guidelines is the main but not the only key leading to lower mortality and rehospitalization. Our data provide satisfying low hard outcomes, but solving the non-compliance behavior and optimizing the non-pharmacological approach should be done comprehensively by the HF team.
Downloads
References
2. Bragazzi NL, Zhong W, Shu J, Much AA, Lotan D, Grupper A, Younis A, Dai H. Burden of Heart Failure and Underlying Causes in 195 Countries and Territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28:1682-1690.
3. Reyes EB, Ha J, Firdaus I, Mohd A, Phrommintikul A, Sim D, Nga Q, Wah C, Yin W, Cowie MR. Heart Failure Across Asia : Same Healthcare Burden but Differences in Organization of Care. Int J Cardiol. 2016;223:163-167.
4. Solomon SD, Anavekar N, Skali H, Mcmurray JJ V, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. Circulation. 2005;112:3738-3744.
5. Xu YU, Shi Y, Zhu Z, Cui C, Li BEI, Chen F, Li DAN, Chen S, Guo Y. Prognosis of Patients with Heart Failure and Reduced Ejection Fraction in China. Exp Ther Med. 2013;6:1437-1442.
6. Lam CSP, Gamble GD, Ling LH, Sim D, Toh K, Leong G, Shuan P, Yeo D, Ong HY, Jaufeerally F, Ng TP, Cameron VA, Poppe K, Lund M, Devlin G, Troughton R, Richards AM, Doughty RN. Mortality Associated with Heart Failure with Preserved vs. Reduced Ejection Fraction in a Prospective International Multi-Ethnic Cohort Study. Eur Heart J. 2018;39:1770-1780.
7. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global Burden of Heart Failure : A Comprehensive and Updated Review of Epidemiology. Cardiovasc Res. 2022;0:1-16.
8. Deswal A, Drazner MH, Fedson SE, Fonarow GC, Hayek SS, Sandhu AT, Stevenson LW, Vardeny O. 2022 AHA / ACC / HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines.; 2022.
9. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology ( ESC ) Developed with the special contribution. Circulation. 2022;145:895-1032.
10. Siswanto BB, Hersunarti N, Erwinanto, Barack R, Pratikto RS, Nauli SE, Lubis AC. Pedoman Tatalaksana Gagal Jantung. Vol 1.; 2015.
11. Hersunarti N, Siswanto BB, Erwinanto, Nauli SE, Lubis AC, Wiryawan N, Dewi PP, Pratikto RS, Hasanah DY. Pedoman Tatalaksana Gagal Jantung. Vol 2.; 2020.
12. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases : A Historical Perspective. Lancet. 2014;383:1933-1945.
13. Irnizarifka, Arifianto H. The COmprehensive Registry and rEsearch on Heart Failure (CORE-HF): 2 Years Report from Single-Centre Indonesian Heart Failure Clinic Registry. Acta Cardiol Indones. 2021;7:13-22.
14. Lang RM, Badano LP, Mor-avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults : An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14.
15. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults : Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2018;32:1-64.
16. Vergaro G, Gentile F, Meems LMG, Aimo A, Januzzi JL, Richards AM, et al. NT-proBNP for Risk Prediction in Heart Failure. JACC Hear Fail. 2021;9:653-663.
17. Magalhães J, Soares F, Noya M, Neimann G, Andrade L, Correia L. NT-ProBNP at Admission Versus NT-ProBNP at Discharge as a Prognostic Predictor in Acute Decompensated Heart Failure. 2017;30:469-475.
18. Pascual-figal D, Wachter R, Senni M, Bao W, Schwende H, Butylin D, Prescott MF. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction. JACC Hear Fail. 2020;8:822-833.
19. Macdonald MR, Tay WT, Teng TK, Anand I, Ling LH, Yap J, Tromp J, Wander GS, Naik A, Ngarmukos T, Siswanto BB, Hung C, Richards AM, Lam CSP. Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia : Outcomes in ASIAN-HF Registry. J Am Hear Assoc. 2020;9:1-15.
20. Crespo-leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT) : 1-Year Follow-Up Outcomes and Differences Across Regions. Eur J Heart Fail. 2016;18:613-625.
21. Ang N, Chandramouli C, Yiu K, Lawson C, Tromp J. Heart Failure and Multimorbidity in Asia. Curr Heart Fail Rep. 2023;20:24-32.
22. Irnizarifka I, Ristiansah IH, Arifianto H. Should We Retain Half-Dose ARNIs in HFrEF ? Lessons Learned from Reverse Remodeling using CORE-HF Real-World Data. Int Cardiovasc Res J. 2022;16:97-102.
Full text (PDF) downloads: 695
Copyright (c) 2023 Indonesian Journal of Cardiology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
